Head of
- Parkinson Study Group Chair, Executive Committee (2012-2024) 1996 -
- Contact Info
Michael Schwarzschild, MD, PhD
Positions
- Professor, Massachusetts General Hospital
Location
-
M
-
Boston, M
-
MA
-
Boston, MA
Clinical Disciplines
Beeson awardee
- Affiliation
- Publications
- Research
- Other
- View All
Affiliation
Clinical Activities
- Movement disorders neurologist Caring for people with Parkinson's disease and related disorders 1994 -
Publications
Selected Publications
-
article
-
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial..
JAMA neurology.
78:312-320.
2021
-
Genetic diversity of axon degenerative mechanisms in models of Parkinson's disease..
Neurobiology of disease.
-.
2021
-
Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned..
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
17:1393-1405.
2020
-
Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study..
Journal of Parkinson's disease.
10:505-510.
2020
-
Barriers and Motivators to Engage in Exercise for Persons with Parkinson's Disease..
Journal of Parkinson's disease.
10:1293-1299.
2020
-
Big health data and Parkinson's disease epidemiology: Challenges and opportunities..
Parkinsonism & related disorders.
58-59.
2020
-
Chasing Protection in Parkinson's Disease: Does Exercise Reduce Risk and Progression?.
Frontiers in aging neuroscience.
-.
2020
- Correction: Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists.. Genetics in medicine : official journal of the American College of Medical Genetics. 22:-. 2020
-
Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD)..
Annals of clinical and translational neurology.
8:308-320.
2020
-
Diet pattern and prodromal features of Parkinson disease..
Neurology.
95:e2095-e2108.
2020
-
Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?.
Neurology.
94:481-494.
2020
-
Does Serum Urate Change as Parkinson's Disease Progresses?.
Journal of Parkinson's disease.
10:1571-1576.
2020
-
GBA.
Neurology.
95:e685-e696.
2020
-
If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames?.
Movement disorders : official journal of the Movement Disorder Society.
35:1727-1730.
2020
-
Imaging Neurochemistry and Brain Structure Tracks Clinical Decline and Mechanisms of ALS in Patients..
Frontiers in neurology.
-.
2020
-
LRRK2.
Neurology.
95:e3428-e3437.
2020
-
Long-Term Use of Antibiotics and Risk of Parkinson's Disease in the Nurses' Health Study..
Parkinson's disease.
-.
2020
-
Plasma Metabolomic Markers of Insulin Resistance and Diabetes and Rate of Incident Parkinson's Disease..
Journal of Parkinson's disease.
10:1011-1021.
2020
-
Pre-diagnostic plasma lipid levels and the risk of amyotrophic lateral sclerosis..
Amyotrophic lateral sclerosis & frontotemporal degeneration.
22:133-143.
2020
-
Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists..
Genetics in medicine : official journal of the American College of Medical Genetics.
22:574-580.
2019
-
Higher urate in LRRK2 mutation carriers resistant to Parkinson disease..
Annals of neurology.
85:593-599.
2019
- Lifestyle and Parkinson's disease progression.. Movement disorders : official journal of the Movement Disorder Society. 34:7-8. 2019
-
Physical activity and prodromal features of Parkinson disease..
Neurology.
93:e2157-e2169.
2019
-
Plasma urate concentrations and possible REM sleep behavior disorder..
Annals of clinical and translational neurology.
6:2368-2376.
2019
-
Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis..
Neurology.
92:e2089-e2100.
2019
- Reply to "Mitochondrial DNA deletions discriminate affected from unaffected LRRK2 mutation carriers".. Annals of neurology. 86:326-327. 2019
-
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases..
Neurology.
92:329-337.
2019
-
Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial..
Neurology.
93:e1328-e1338.
2019
-
Appendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women..
Movement disorders : official journal of the Movement Disorder Society.
33:1492-1496.
2018
-
Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice..
EBioMedicine.
13-22.
2018
-
Cardiovascular Safety of Febuxostat..
The New England journal of medicine.
379:-.
2018
-
Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease..
EBioMedicine.
259-268.
2018
-
Genetic variants related to urate and risk of Parkinson's disease..
Parkinsonism & related disorders.
4-9.
2018
-
Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts..
Neurology.
90:e1646-e1653.
2018
-
Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk..
Movement disorders : official journal of the Movement Disorder Society.
33:414-420.
2018
-
Non-motor features of Parkinson's disease in a nested case-control study of US men..
Journal of neurology, neurosurgery, and psychiatry.
89:1288-1295.
2018
-
Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis..
Annals of clinical and translational neurology.
5:1522-1533.
2018
-
Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral sclerosis..
Neurology.
92:e2081-e2088.
2018
- The association between restless legs syndrome and premotor symptoms of Parkinson's disease.. Journal of the neurological sciences. 41-44. 2018
-
Air Pollution and Risk of Parkinson's Disease in a Large Prospective Study of Men..
Environmental health perspectives.
125:-.
2017
-
Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials..
Movement disorders : official journal of the Movement Disorder Society.
32:319-324.
2017
-
Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?.
Journal of Parkinson's disease.
7:79-80.
2017
- Dietary antioxidants and Parkinson's disease.. Movement disorders : official journal of the Movement Disorder Society. 32:1501-1503. 2017
-
Differences in Parkinson's Disease Risk with Caffeine Intake and Postmenopausal Hormone Use..
Journal of Parkinson's disease.
7:677-684.
2017
-
Intake of dairy foods and risk of Parkinson disease..
Neurology.
89:46-52.
2017
-
KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients..
Proceedings of the National Academy of Sciences of the United States of America.
114:E4676-E4685.
2017
-
MC1R.
Annals of clinical and translational neurology.
4:212-216.
2017
-
Pre-diagnostic plasma urate and the risk of amyotrophic lateral sclerosis..
Amyotrophic lateral sclerosis & frontotemporal degeneration.
19:194-200.
2017
- Targeting urate to reduce oxidative stress in Parkinson disease.. Experimental neurology. 298:210-224. 2017
-
The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival..
Annals of neurology.
81:395-406.
2017
-
Urate as a Marker of Risk and Progression of Neurodegenerative Disease..
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
14:148-153.
2017
-
Intake of antioxidant vitamins and risk of Parkinson's disease..
Movement disorders : official journal of the Movement Disorder Society.
31:1909-1914.
2016
-
Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors..
Neuroscience.
129-37.
2016
-
Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease..
Movement disorders : official journal of the Movement Disorder Society.
31:417-21.
2016
-
Prospective study of plasma urate and risk of Parkinson disease in men and women..
Neurology.
86:520-6.
2016
-
Purines: forgotten mediators in traumatic brain injury..
Journal of neurochemistry.
137:142-53.
2016
-
Serum urate at trial entry and ALS progression in EMPOWER..
Amyotrophic lateral sclerosis & frontotemporal degeneration.
18:120-125.
2016
-
The epidemiology of Parkinson's disease: risk factors and prevention..
The Lancet. Neurology.
15:1257-1272.
2016
-
Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease..
Brain : a journal of neurology.
138:2659-71.
2015
-
Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release..
Neurobiology of disease.
574-579.
2015
-
The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia..
PloS one.
10:-.
2015
-
A prospective analysis of airborne metal exposures and risk of Parkinson disease in the nurses' health study cohort..
Environmental health perspectives.
122:933-8.
2014
- Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's disease.. Brain research. 103-9. 2014
-
Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss..
PloS one.
9:-.
2014
-
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial..
JAMA neurology.
71:141-50.
2014
-
Mendelian randomization of serum urate and parkinson disease progression..
Annals of neurology.
76:862-8.
2014
-
Particulate matter and risk of Parkinson disease in a large prospective study of women..
Environmental health : a global access science source.
-.
2014
-
Protection by inosine in a cellular model of Parkinson's disease..
Neuroscience.
242-9.
2014
-
Restless legs syndrome: an early clinical feature of Parkinson disease in men..
Sleep.
37:369-72.
2014
- Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 11:34-46. 2014
- Urate and neuroprotection trials.. The Lancet. Neurology. 13:-. 2014
-
Caffeine consumption and risk of dyskinesia in CALM-PD..
Movement disorders : official journal of the Movement Disorder Society.
28:380-3.
2013
-
Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments..
Journal of Parkinson's disease.
3:231-9.
2013
-
Postmortem brain levels of urate and precursors in Parkinson's disease and related disorders..
Neuro-degenerative diseases.
12:189-98.
2013
-
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study..
Neurology.
81:1531-7.
2013
- Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease.. Annals of neurology. 71:278-82. 2012
- Adenosine A2A receptors modulate glutamate uptake in cultured astrocytes and gliosomes.. Glia. 60:702-16. 2012
-
Age, statin use, and the risk for incident Parkinson disease-reply..
Archives of neurology.
69:-.
2012
-
Alcohol and risk of Parkinson's disease in a large, prospective cohort of men and women..
Movement disorders : official journal of the Movement Disorder Society.
27:980-7.
2012
-
Caffeine and risk of Parkinson's disease in a large cohort of men and women..
Movement disorders : official journal of the Movement Disorder Society.
27:1276-82.
2012
-
Caffeine in Parkinson disease: better for cruise control than snooze patrol?.
Neurology.
79:616-8.
2012
- Conditional neural knockout of the adenosine A(2A) receptor and pharmacological A(2A) antagonism reduce pilocarpine-induced tremulous jaw movements: studies with a mouse model of parkinsonian tremor.. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 23:972-7. 2012
- Declining quality of life in Parkinson disease before and after diagnosis.. Journal of Parkinson's disease. 2:153-60. 2012
- Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration.. Proceedings of the National Academy of Sciences of the United States of America. 110:300-5. 2012
-
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease..
Movement disorders : official journal of the Movement Disorder Society.
27:1392-7.
2012
-
Efficient determination of purine metabolites in brain tissue and serum by high-performance liquid chromatography with electrochemical and UV detection..
Biomedical chromatography : BMC.
27:122-9.
2012
-
Habitual intake of dietary flavonoids and risk of Parkinson disease..
Neurology.
78:1138-45.
2012
-
Prospective study of statin use and risk of Parkinson disease..
Archives of neurology.
69:380-4.
2012
- Protection of dopaminergic cells by urate requires its accumulation in astrocytes.. Journal of neurochemistry. 123:172-81. 2012
-
Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease..
PloS one.
7:-.
2012
- Urate in Parkinson's disease: more than a biomarker?. Current neurology and neuroscience reports. 12:367-75. 2012
-
A prospective study of bowel movement frequency and risk of Parkinson's disease..
American journal of epidemiology.
174:546-51.
2011
-
Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study..
Movement disorders : official journal of the Movement Disorder Society.
26:2283-6.
2011
- Obesity, diabetes, and risk of Parkinson's disease.. Movement disorders : official journal of the Movement Disorder Society. 26:2253-9. 2011
- Preclinical jockeying on the translational track of adenosine A2A receptors.. Experimental neurology. 228:160-4. 2011
-
Serum cholesterol and the progression of Parkinson's disease: results from DATATOP..
PloS one.
6:-.
2011
- Serum urate and probability of dopaminergic deficit in early "Parkinson's disease".. Movement disorders : official journal of the Movement Disorder Society. 26:1864-8. 2011
-
Use of ibuprofen and risk of Parkinson disease..
Neurology.
76:863-9.
2011
-
Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration..
Experimental neurology.
223:657-61.
2010
-
Calcium channel blocker use and risk of Parkinson's disease..
Movement disorders : official journal of the Movement Disorder Society.
25:1818-22.
2010
- Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.. Brain research. 310-8. 2010
-
Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease..
Neuroscience.
167:475-81.
2010
- Pathophysiological roles for purines: adenosine, caffeine and urate.. Progress in brain research. 183-208. 2010
- Plasma urate and Parkinson's disease in women.. American journal of epidemiology. 172:666-70. 2010
-
Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women..
Parkinsonism & related disorders.
16:370-5.
2010
-
Prenatal and early life factors and risk of Parkinson's disease..
Movement disorders : official journal of the Movement Disorder Society.
25:1560-7.
2010
- Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease.. Neuroscience letters. 486:161-5. 2010
- Rasagiline in Parkinson's disease.. The New England journal of medicine. 362:658; author reply 658-9. 2010
- Restless legs syndrome and Parkinson's disease in men.. Movement disorders : official journal of the Movement Disorder Society. 25:2654-7. 2010
-
Restless legs syndrome and erectile dysfunction..
Sleep.
33:75-9.
2010
- The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?. Neurology. 75:1943-4; author reply 1944-5. 2010
-
Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis..
Biomarkers in medicine.
4:701-12.
2010
-
Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease..
Journal of neuropathology and experimental neurology.
68:515-24.
2009
- Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 6:141-51. 2009
- Family history of melanoma and Parkinson disease risk.. Neurology. 73:1286-91. 2009
-
Genetic determinants of hair color and Parkinson's disease risk..
Annals of neurology.
65:76-82.
2009
- Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease.. Journal of neurochemistry. 111:1478-89. 2009
- Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway.. TheScientificWorldJournal. 1321-44. 2009
-
Obesity and restless legs syndrome in men and women..
Neurology.
72:1255-61.
2009
- Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease.. Movement disorders : official journal of the Movement Disorder Society. 24:1359-65. 2009
-
Smoking and Parkinson's disease: using parental smoking as a proxy to explore causality..
American journal of epidemiology.
169:678-82.
2009
-
Urate as a predictor of the rate of clinical decline in Parkinson disease..
Archives of neurology.
66:1460-8.
2009
- Adenosine A1 and A2A receptor regulation of protein phosphatase 2A in the murine heart.. Journal of cellular physiology. 216:83-90. 2008
-
Diet, urate, and Parkinson's disease risk in men..
American journal of epidemiology.
167:831-8.
2008
-
Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007..
Environmental health perspectives.
117:117-21.
2008
- Mice heterozygous for both A1 and A(2A) adenosine receptor genes show similarities to mice given long-term caffeine.. Journal of applied physiology (Bethesda, Md. : 1985). 106:631-9. 2008
- Perceived imbalance and risk of Parkinson's disease.. Movement disorders : official journal of the Movement Disorder Society. 23:613-6. 2008
- Plasma urate and progression of mild cognitive impairment.. Neuro-degenerative diseases. 6:23-8. 2008
-
Recreational physical activity and risk of Parkinson's disease..
Movement disorders : official journal of the Movement Disorder Society.
23:69-74.
2008
-
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease..
Archives of neurology.
65:716-23.
2008
- Telomere length and risk of Parkinson's disease.. Movement disorders : official journal of the Movement Disorder Society. 23:302-5. 2008
- Adenosine A(2A) receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus.. Journal of neurochemistry. 104:279-86. 2007
- Adenosine A2A antagonists as neurotherapeutics: crossing the bridge.. Progress in neurobiology. 83:261-2. 2007
- Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?. Current opinion in neurology. 20:477-83. 2007
-
Consumption of dairy products and risk of Parkinson's disease..
American journal of epidemiology.
165:998-1006.
2007
- Erectile function and risk of Parkinson's disease.. American journal of epidemiology. 166:1446-50. 2007
-
Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease..
Neurology.
69:1688-95.
2007
-
Molecular markers of early Parkinson's disease based on gene expression in blood..
Proceedings of the National Academy of Sciences of the United States of America.
104:955-60.
2007
- Peripheral inflammatory biomarkers and risk of Parkinson's disease.. American journal of epidemiology. 167:90-5. 2007
-
Plasma urate and risk of Parkinson's disease..
American journal of epidemiology.
166:561-7.
2007
-
Prospective study of dietary pattern and risk of Parkinson disease..
The American journal of clinical nutrition.
86:1486-94.
2007
-
Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications..
Progress in neurobiology.
83:293-309.
2007
-
Temporal relationship between cigarette smoking and risk of Parkinson disease..
Neurology.
68:764-8.
2007
-
A prospective study of night shift work, sleep duration, and risk of Parkinson's disease..
American journal of epidemiology.
163:726-30.
2006
-
Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis..
British journal of pharmacology.
148:1144-55.
2006
-
Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma..
Arthritis and rheumatism.
54:2632-42.
2006
- Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.. The Journal of neuroscience : the official journal of the Society for Neuroscience. 26:535-41. 2006
- Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.. The Journal of neuroscience : the official journal of the Society for Neuroscience. 26:13548-55. 2006
-
Novel pharmacological targets for the treatment of Parkinson's disease..
Nature reviews. Drug discovery.
5:845-54.
2006
-
Pesticide exposure and risk for Parkinson's disease..
Annals of neurology.
60:197-203.
2006
- Survival of Parkinson's disease patients in a large prospective cohort of male health professionals.. Movement disorders : official journal of the Movement Disorder Society. 21:1002-7. 2006
-
Targeting adenosine A2A receptors in Parkinson's disease..
Trends in neurosciences.
29:647-54.
2006
- (E)-8-(3-Chlorostyryl)-1,3,7-trimethylxanthine, a caffeine derivative acting both as antagonist of adenosine A2A receptors and as inhibitor of MAO-B.. Acta crystallographica. Section C, Crystal structure communications. 61:o531-2. 2005
- A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 30:891-900. 2005
- Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience.. Drugs & aging. 22:471-82. 2005
- Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia.. Journal of neurochemistry. 95:919-29. 2005
- Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-D-aspartate effects.. Journal of neurochemistry. 95:1188-200. 2005
-
Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine..
Nature neuroscience.
8:858-9.
2005
- Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice.. Neuroscience letters. 393:31-5. 2005
- Genetic and pharmacological inactivation of adenosine A2A receptor reveals an Egr-2-mediated transcriptional regulatory network in the mouse striatum.. Physiological genomics. 23:89-102. 2005
- Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice.. The Journal of neuroscience : the official journal of the Society for Neuroscience. 25:10414-9. 2005
-
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease..
Annals of neurology.
58:963-7.
2005
-
Physical activity and the risk of Parkinson disease..
Neurology.
64:664-9.
2005
- Characterization of genomic organization of the adenosine A2A receptor gene by molecular and bioinformatics analyses.. Brain research. 1000:156-73. 2004
-
Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32..
Molecular pharmacology.
65:121-9.
2004
-
Folate intake and risk of Parkinson's disease..
American journal of epidemiology.
160:368-75.
2004
- Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage.. Journal of neurochemistry. 88:538-44. 2004
-
Obesity and the risk of Parkinson's disease..
American journal of epidemiology.
159:547-55.
2004
-
Tetanus toxin fragment C as a vector to enhance delivery of proteins to the CNS..
Brain research.
1011:7-13.
2004
-
Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease..
Pharmacology & therapeutics.
105:267-310.
2004
-
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease..
Experimental neurology.
184:285-94.
2003
- Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.. Neurology. 61:S74-81. 2003
- Alcohol consumption and the incidence of Parkinson's disease.. Annals of neurology. 54:170-5. 2003
-
Caffeine, postmenopausal estrogen, and risk of Parkinson's disease..
Neurology.
60:790-5.
2003
- DARPP chocolate: a caffeinated morsel of striatal signaling.. Science's STKE : signal transduction knowledge environment. 2003:-. 2003
- Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 28:1086-95. 2003
-
Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists..
Bioorganic & medicinal chemistry.
11:1299-310.
2003
- Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists.. Neurology. 61:S62-8. 2003
- Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.. Neurobiology of aging. 24:245-58. 2003
-
Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease..
Neurology.
61:S55-61.
2003
-
Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease..
Archives of neurology.
60:1059-64.
2003
- Prospective study of phobic anxiety and risk of Parkinson's disease.. Movement disorders : official journal of the Movement Disorder Society. 18:646-51. 2003
-
Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells..
The Journal of clinical investigation.
112:883-91.
2003
- Sleep regulation in adenosine A2A receptor-deficient mice.. Neurology. 61:S94-6. 2003
- 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism.. The Journal of biological chemistry. 277:36040-4. 2002
-
Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors..
The American journal of pathology.
160:2009-18.
2002
- Caffeinated clues and the promise of adenosine A(2A) antagonists in PD.. Neurology. 58:1154-60. 2002
- Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice.. Neuroscience letters. 322:13-6. 2002
- Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors.. The Journal of neuroscience : the official journal of the Society for Neuroscience. 22:1054-62. 2002
-
Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin..
The American journal of pathology.
160:2231-44.
2002
- Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice.. The Biochemical journal. 354:123-30. 2001
-
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease..
The Journal of neuroscience : the official journal of the Society for Neuroscience.
21:-.
2001
- The parkinsonian neurotoxin, MPP+ induces phosphorylated c-Jun in dopaminergric neurons of mesencephalic cultures.. Parkinsonism & related disorders. 8:19-22. 2001
-
The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice..
Proceedings of the National Academy of Sciences of the United States of America.
98:1970-5.
2001
-
Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms..
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
14:2065-74.
2000
-
Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: a potential vector for delivering heterologous proteins to neurons..
Journal of neurochemistry.
74:2528-36.
2000
- Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors.. Neuroscience. 97:195-204. 2000
- Study of A(2A) adenosine receptor gene deficient mice reveals that adenosine analogue CGS 21680 possesses no A(2A) receptor-unrelated lymphotoxicity.. British journal of pharmacology. 131:43-50. 2000
-
A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice..
The Journal of neuroscience : the official journal of the Society for Neuroscience.
19:9192-200.
1999
- Contrasting calcium dependencies of SAPK and ERK activations by glutamate in cultured striatal neurons.. Journal of neurochemistry. 72:2248-55. 1999
-
Glutamate, but not dopamine, stimulates stress-activated protein kinase and AP-1-mediated transcription in striatal neurons..
The Journal of neuroscience : the official journal of the Society for Neuroscience.
17:3455-66.
1997
- Normal-pressure hydrocephalus with misleading features of irreversible dementias: a case report.. Journal of geriatric psychiatry and neurology. 10:51-4. 1997
- Hemiballismus.. AJNR. American journal of neuroradiology. 15:1377-82. 1994
- Leukemia inhibitory factor and ciliary neurotrophic factor increase activated Ras in a neuroblastoma cell line and in sympathetic neuron cultures.. Journal of neurochemistry. 63:1246-54. 1994
- Effects of peptides of the secretin-glucagon family and cyclic nucleotides on tyrosine hydroxylase activity in sympathetic nerve endings.. Journal of neurochemistry. 56:400-6. 1991
- Activation of ganglionic tyrosine hydroxylase by peptides of the secretin-glucagon family: structure-function studies.. Neuroscience. 31:159-67. 1989
-
Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation..
Annual review of neuroscience.
415-61.
1989
- Secretin and vasoactive intestinal peptide activate tyrosine hydroxylase in sympathetic nerve endings.. The Journal of neuroscience : the official journal of the Society for Neuroscience. 9:160-6. 1989
- Both synaptic and antidromic stimulation of neurons in the rat superior cervical ganglion acutely increase tyrosine hydroxylase activity.. Neuroscience. 25:207-15. 1988
-
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial..
JAMA neurology.
78:312-320.
2021
Research
Principal Investigator on
- Planning for Prevention of Parkinson's Disease: a trial design forum 2023 - 2028
- Urate-LRRK2 interactions in Parkinson's disease 2019 - 2025
- Tele-Health Extension for Phase 3 Parkinson's Disease Trial Cohorts 2018 - 2024
- Phase 3 trial of inosine for Parkinson's disease CCC 2015 - 2023
- 2019 Parkinson Study Group Symposium and Training 2019 - 2022
- 2017 Parkinson Study Group Symposium and Training 2017 - 2018
- 2016 Parkinson Study Group Symposium and Training 2016 - 2017
- 2014 Parkinson Study Group Symposium and Training 2014 - 2015
- Role of urate in protecting mitochondrial function in the brain 2013 - 2015
- 2013 Parkinson's Study Group Symposium 2013 - 2014
- Pursuing purine pathways to clinical trials for Parkinson's disease 2008 - 2014
- Pursuing purinergic pathways to clinical trials for Parkinson's disease 2008 - 2013
- Translational Foundation of Adenosine Antagonist Use for Dyskinesias 2006 - 2012
- Uric Acid:novel therapeutic target for Parkinson's Disease 2009 - 2011
- Targeting Adenosine A2A Receptors in Parkinson's Disease 2006 - 2007
- ASSESS THE EFFICACY & SAFETY OF CEP-1347 IN PTS W/EARLY PARKINSON'S DISEASE 2005 - 2006
- A2A Adenosine Receptors in Psychostimulant Sensitization 2001 - 2006
- Novel Neuroprotection by Caffeine in Parkinson's Disease 2001 - 2006
- Assess the Efficacy & Safety of CEP-1347 in Pts w/Early Parkinson's Disease 2003 - 2004
- Translating A2A Receptor Biology into Novel PD Therapy 2002 - 2003
- A2A ADENOSINE RECEPTOR--A NOVEL ROLE IN NEUROPROTECTION 2000 - 2001
- ADENOSINE A2 RECEPTORS AND PSYCHOSTIMULANT INTERACTIONS 1992 - 2001
- RAS AND NEURONAL GENE REGULATION BY CNTF 1994 - 1999
Other
Available to Provide Advice to Those
Available to be Contacted for
Areas of Focus
- Parkinson's disease